WASHINGTON — The Food and Drug Administration’s review and approval of a controversial Alzheimer’s drug was “rife with irregularities,” including dozens of
Tag - Alzheimer’s
Cortexyme, pressing forward after its novel approach to Alzheimer’s disease failed in a mid-stage trial, believes a lower dose of the medicine might safely
One morning in 2012, my wife Geri looked in the mirror and failed to recognize her own face. Our neurologist diagnosed Geri, a former health care executive and
